Innovation Stage
Expo Hall, #852

ACC.17 MediaLooking for something different? Check out ACC’s Innovation Stage — a unique theater that provides an opportunity to enjoy a 30-minute, focused discussion in a relaxed setting.

  Saturday, March 10
  Saturday, March 10

9:45 a.m. – 10:15 a.m.

PRALUENT® (alirocumab) Injection: The Time to Treat is Now
Dean G. Karalis, MD
Sponsored by Sanofi Regeneron

10:45 a.m. – 11:15 a.m.

Thrombosis: AFib & DVT/PE: An Exploration in Risk Reduction
Dharmesh Patel, MD, FACC; Cardiologist Stern Cardiovascular Foundation
Sponsored by Janssen Pharmaceuticals, Inc.

DVT/PE: This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism and how they can reduce the risk of recurrent thrombotic events.

This session is open to ACC.18 attendees with full access badges only.

12:30 p.m. – 1:00 p.m.

Thrombosis: AFib & DVT/PE: An Exploration in Risk Reduction
William J. French, MD; Professor of Medicine David Geffen School of Medicine at UCLA Director, Cardiac Catheterization Laboratory Director, Anticoagulation Clinic Harbor-UCLA Medical Center
Sponsored by Janssen Pharmaceuticals, Inc.

DVT/PE: This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism and how they can reduce the risk of recurrent thrombotic events.

This session is open to ACC.18 attendees with full access badges only.

1:30 p.m. – 2:00 p.m.

Thrombosis: AFib & DVT/PE: An Exploration in Risk Reduction
Marc Cohen, MD, FACC, FACP, FSCAI, FAHA; Chief, Division of Cardiology Newark Beth Israel Medical Center Newark, New Jersey Professor of Medicine Rutgers New Jersey Medical School
Sponsored by Janssen Pharmaceuticals, Inc.

AFib:This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

This session is open to ACC.18 attendees with full access badges only.

3:45 p.m. – 4:15 p.m.

Modern Afib Treatments For a Better Tomorrow
Marcelo A. Jimenez, MD, FHRS; Cardiac Electrophysiologist, JFK Medical Center
Sponsored by Biosense Webster, Inc.

Atrial fibrillation has become a virtual epidemic with over 3 million patients in the U.S. alone affected. For some of these patients, current pharmacological therapies are not effective.

We want to engage in a practical discussion about the diagnosis, progression, and treatment for atrial fibrillation by reviewing various patient cases. In addition to reviewing clinical information, we are going to discuss the patient management pathway for atrial fibrillation.

Please attend this seminar as the knowledge shared during this presentation will help us evaluate and discuss the continuum of treatment options with our atrial fibrillation patients.

This session is open to ACC.18 attendees with full access badges only.

  Sunday, March 11
  Sunday, March 11

9:45 a.m. – 10:15 a.m.

PRALUENT® (alirocumab) Injection: Addressing the Unmet Need and Getting Patients to Goal
Dr. Norman Lepor, MD, FACC
Sponsored by Sanofi Regeneron

12:30 p.m. – 1:00 p.m.

HF ORIGINS: New Perspectives on the Pathophysiology of Depressed Myocardial Contractility in Heart Failure with Reduced Ejection Fraction
Dr. John Teerlink
Sponsored by Amgen

1:30 p.m. – 2:00 p.m.

I’m Afraid to Faint Again: Overview of Neurogenic Orthostatic Hypotension Diagnosis and Management
Sameh Mobarek, MD, FAAC
Sponsored by Lundbeck

Orthostatic hypotension caused by dysautonomia — also known as neurogenic orthostatic hypotension (nOH) — can have a profound impact on patients’ lives, but may be difficult to identify and diagnose. Learn more about how to recognize the symptoms of nOH as well as some common diagnostic and non-pharmacologic management approaches.

3:45 p.m. – 4:15 p.m.

Right Heart Matters: A Cardiologist’s Perspective on Pulmonary Hypertension
Anjali Vaidya, MD
Andrew Pogozelski, MD

Sponsored by Bayer Healthcare

Today’s program will highlight the importance of considering the right heart when a cardiologist is interpreting patient clinical signs and symptoms. During this discussion, PAH experts will discuss a PAH treatment option.

  Monday, March 12
  Monday, March 12

9:45 a.m. – 10:15 a.m.

Renal Function-Based Contrast Dosing for Acute Kidney Injury Prevention
Hitinder Gurm, MD FSCAI; Professor of Medicine, Associate Chief Clinical Officer, CVC/Neuro, University of Michigan
Sponsored by Osprey Medical, Inc.

Excess volumes of contrast are associated with renal complications in patients undergoing cardiac procedures. Recently published research outlines the importance of reducing contrast volumes when treating high-risk patients in the cath lab and the potential patient and financial benefits.

Please join us to learn more about the research of setting contrast thresholds in the cath lab, why this may impact patient outcomes and healthcare economics, and how to incorporate contrast thresholds into clinical practice in conjunction with overall practice guidelines.

12:30 p.m. – 1:00 p.m.

Patient Stands Up, Blood Pressure Goes Down: Diagnostic and Management Considerations For Neurogenic Orthostatic Hypotension
Brian Olshansky, MD
Salima Brillman, MD

Sponsored by Lundbeck

A lively dual presentation between a Cardiologist and Neurologist on how to identify and treat patients with orthostatic hypotension caused by dysautonomia — also known as neurogenic orthostatic hypotension (nOH). Presentation will also include a brief overview of nOH as well as practical and useful diagnostic and management strategies.

Schedule is current as of Feb. 2, 2017, and is subject to change. Please check back for updates.


*Innovation Stage presentations are not part of ACC.18, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Advertisement

ACC Logo
ACC.18 on Social Media:
      
2017 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Contact Us